For the study, INVEST randomly assigned 6 400 patients with diabetes and CAD to blood pressure-lowering therapy based on either a calcium channel blocker or a beta-blocker, plus an angiotensin converting enzyme (ACE) inhibitor and/ or a thiazide diuretic. This evidence concerns the gene ACE and coronary artery disorder.